82 / 84
82
necrosis factor-alpha treatment. J Rheumatol
2008;35:855-61.
65. Delaunay C, Farrenq V, Marini-Portugal A,
Cohen JD, Chevalier X, Claudepierre P. Infliximab
to
etanercept
switch
in
patients
with
spondyloarthropathies and psoriatic arthritis:
preliminary data. J Rheumatol 2005;32:2183-5.63.
66. Cantini F, Niccoli L, Benucci M, Chindamo D,
Nannini C, Olivieri I, et al. Switching from
infliximab to once-weekly administration of 50 mg
etanercept in resistant or intolerant patients with
ankylosing spondylitis: results of a fifty-four-week
study. Arthritis Rheum 2006;55:812-6.
67. Conti F, Ceccarelli F, Marocchi E, Magrini L,
Spinelli FR, Spadaro A, et al. Switching tumour
necrosis factor alpha antagonists in patients with
ankylosing spondylitis and psoriatic arthritis: an
observational study over a 5-year period. Ann
Rheum Dis 2007;66:1393-7.
68. Coates LC, Cawkwell LS, Ng NW, Bennett AN,
Bryer DJ, Fraser AD, et al. Real life experience
confirms sustained response to long-term biologics
and
switching
in
ankylosing
spondylitis.
Rheumatology (Oxford) 2008;47:897-900.
69. Pradeep DJ, Keat AC, Gaffney K, Brooksby A,
Leeder J, Harris C. Switching anti-TNF therapy in
ankylosing spondylitis. Rheumatology (Oxford)
2008;47:1726-7.